2022 Volume 18 Issue 5-6 Pages 408-415
Anti-tumor necrosis factor (TNF) alpha agent treatment is effective for ulcerative colitis (UC) and Crohn’s disease (CD). We conducted a systematic review and meta-analysis examining the prevention of surgical site infection（SSI）associated with surgery for UC and CD in patients using anti-TNF agent. (Methods) We performed a systematic literature review until June 2019 and performed meta-analysis. (Results) 13 studies for UC and 16 studies for CD were included. Anti-TNF agent use in patients with UC was not associated with the incisional SSI (odds ratio (OR) 1.04, 95％ confidence interval (CI) (0.47-2.32)) or organ/space SSI (OR 1.85, 95% CI (0.82-4.20)). Anti-TNF agent use in patients with CD was not associated with the incisional SSI (OR 0.98, 95% CI (0.52-1.83)) or organ/space SSI incidence (OR 1.08, 95% CI (0.79-1.48)). (Conclusion) We observed a nonsignificant association between preoperative anti-TNF agent use and SSI in surgery for UC and CD.
